Custom small molecule-conjugated LNP development services covering ligand selection, ligand–lipid conjugate synthesis, surface incorporation, ligand density optimization, payload-matched formulation, and receptor-mediated targeting evaluation.
Small molecule-conjugated lipid nanoparticles (LNPs) are LNPs whose surface displays a low-molecular-weight targeting ligand, usually below about 1,500 Da, held in the particle shell by a lipid anchor. The ligand sits at the outer end of a PEG spacer so it stays reachable by the receptor, while the anchor keeps it in place during circulation. Because the ligand is made by synthesis rather than by biological expression, its structure, loading level, and batch behavior can be measured directly instead of inferred.
Unmodified LNPs have a strong native pull toward the liver. The particle surface picks up apolipoprotein E, and the formulation is then taken up through hepatocyte and liver sinusoidal routes. That is helpful for some programs and unhelpful for others. When a project needs RNA or small-molecule payloads in tumor cells, bone tissue, defined immune-cell subsets, or hepatocytes through a known receptor, the particle needs its own address label. Small-molecule ligands supply that label without the size, cost, and characterization burden of protein ligands.
BOC Sciences works with pharmaceutical and biotechnology teams on targeted LNP development programs built around small-molecule ligands: deciding which ligand fits the receptor, building the ligand–lipid conjugate, installing it at a density that actually works, keeping the payload intact, and then testing whether the uptake is genuinely receptor-driven. We support siRNA, mRNA, saRNA, circRNA, ASO, CRISPR-related RNA, protein, peptide, and small-molecule payloads.
Small Molecule-Functionalized LNP Illustration
BOC Sciences supports the full development chain for small molecule-conjugated LNPs, from ligand chemistry and conjugate synthesis through surface installation, formulation tuning, ligand quantification, and receptor-level evaluation.
The ligand has to survive two things: the chemistry that attaches it to a lipid, and the assembly conditions that build the particle. We start from the receptor, not from the catalogue, and we check the conjugation site before committing to a synthetic route.
Installing the ligand is the step where most projects gain or lose performance. A ligand that is present but buried behaves like no ligand at all, and a ligand loaded too high can destabilize the particle.
Adding a ligand–lipid changes the assembly environment. We treat the ligand layer and the core formulation as one system and re-optimize the lipid ratios after the ligand is introduced, not before.
A ligand density calculated from the feed ratio is an assumption. We measure what is actually on the particle and how much of it is reachable.
The question we try to answer is not "does uptake go up" but "does uptake go up because of the receptor". Serum-free assays overstate targeting, so we design the readout with that bias in mind.
A ligand–lipid that behaves well at 1 mL can behave badly at 50 mL. We work on the preparation conditions early enough that the later scale-up step is not a surprise.
Small-molecule ligands are not one category. They differ in receptor class, charge, solubility, and how much they disturb particle assembly, and those differences drive the whole formulation strategy. BOC Sciences works across the ligand families below and helps clients narrow them to the one or two worth testing first.
Vitamins and vitamin-derived structures bind transporters and receptors that are often overexpressed in rapidly dividing or activated cells, which makes them a practical starting point for tumor and immune-cell work.
Sugar ligands read lectin-type receptors. They are small, hydrophilic, and usually cheap to make, but they need multivalent presentation and enough spacer length to be seen.
Aromatic and heteroaromatic motifs cover some of the most useful non-oncology targets, including sigma receptors and transporter-linked binding sites, and the aromatic ring also helps the conjugate sit correctly in the lipid shell.
Boronic acids form reversible cyclic esters with cis-diol groups, which gives them a binding mechanism that most other small ligands do not have: they recognize sugar residues on the cell surface directly.
Terpenoids and steroids are rigid, lipophilic scaffolds. They are used both as receptor ligands and as membrane-modifying groups that change how the particle behaves after it reaches the cell.
Bisphosphonates bind calcium mineral surfaces with high affinity. On an LNP, that converts a soft organic particle into one that sticks where bone mineral is exposed.
Discuss your target, ligand structure, required attachment chemistry, and payload. BOC Sciences can help design and screen conjugated LNP candidates.
There is no single best way to put a small molecule on an LNP. The right route depends on whether the ligand survives organic solvent, whether the payload has already been encapsulated, and how tightly the ligand density needs to be controlled. BOC Sciences runs our nanoparticle conjugation services across the four routes below and selects the route by testing, not by default.
The ligand–lipid is dissolved with the ionizable lipid, helper lipid, cholesterol, and PEG-lipid, and the whole mixture is assembled in one step. This is the cleanest route when the ligand tolerates the organic phase.
The conjugate is prepared as micelles and incubated with preformed LNPs under controlled temperature and time. The core formulation stays untouched, which makes this the fastest way to run a density series.
A reactive handle is built into the particle surface first, then the ligand is coupled after the payload is already inside. This route protects ligands that would not survive the assembly step.
The ligand is brought to the surface through a high-affinity non-covalent pair. This route is about speed: the same particle batch can carry several different ligands without new chemistry each time.
Small-molecule ligands sit between sugars and biologics on the size scale, and that middle position gives them a practical set of advantages for LNP surface engineering.
Chemically Defined and Manufacturable
A small-molecule ligand has one structure, one molecular weight, and a synthetic route that scales. It is characterized by HPLC and LC-MS rather than by bioassay, which makes batch comparison straightforward. Compare this with antibody-conjugated LNPs, where ligand size and heterogeneity complicate surface quantification.
Low Steric Footprint, High Valency
Because each ligand occupies little surface area, hundreds to thousands of copies can be displayed without crowding the PEG layer. That copy number is what turns a weak monovalent interaction into usable avidity.
Modular Swapping for Tropism Screening
One core LNP formulation can carry several ligand variants, so tropism becomes a variable rather than a reformulation project. Teams comparing ligand classes often pair this work with peptide functionalized LNPs before committing to one direction.
Predictable Analytical Control
Ligand content, ligand accessibility, and particle attributes can all be measured separately. When a targeting result changes, the cause can usually be traced to a number rather than guessed at, unlike aptamer-conjugated LNP systems where folding state also enters the picture.
A targeting ligand only matters if the payload still works after the ligand is installed. BOC Sciences matches the ligand chemistry, the incorporation route, and the loading conditions to the payload class, then verifies both particle attributes and payload function on the same candidate.
| Payload Type | Supported Uses & Small Molecule-LNP Development Considerations | Request Information |
|---|---|---|
| Small Molecule-LNP Development for siRNA | Used for receptor-defined gene silencing in tumor-cell, fibroblast, and immune-cell models. Development covers encapsulation, free RNA reduction, ligand density, uptake selectivity, and knockdown comparison against a matched unmodified LNP. Related capabilities sit under lipid nanoparticles for siRNA delivery. | Inquiry |
| Small Molecule-LNP Development for mRNA and Reporter RNA | Supports reporter expression, protein expression, and antigen-related delivery studies. We track mRNA integrity, encapsulation efficiency, ligand exposure, particle stability, and expression level in receptor-positive versus receptor-low models, drawing on our lipid nanoparticles for mRNA delivery workflow. | Inquiry |
| Small Molecule-LNP Development for saRNA and circRNA | Applicable to RNA formats that need stronger payload protection and longer expression windows. Work focuses on co-formulation stability with the ligand–lipid, storage behavior, and cell-based expression readouts. | Inquiry |
| Small Molecule-LNP Development for ASO | Designed for antisense programs where charge and length differ from siRNA, so loading pH and lipid ratio are re-tuned. See lipid nanoparticles for ASO delivery for the base formulation approach. | Inquiry |
| Small Molecule-LNP Development for gRNA/mRNA and CRISPR RNP | Supports co-loaded nucleic acid systems and protein–RNA complexes that need ratio control and particle uniformity. We check whether the ligand–lipid shifts complexation behavior before advancing to functional editing readouts, using our lipid nanoparticles for CRISPR RNP delivery experience. | Inquiry |
| Small Molecule-LNP Development for Protein and Peptide | Suitable for enzymes, antigens, binding proteins, and functional peptides. Formulation work uses mild loading conditions, aggregation control, and activity retention checks, supported by protein encapsulation in LNPs. | Inquiry |
| Small Molecule-LNP Development for Small Molecule Drugs | Built for hydrophobic, amphiphilic, or weakly ionizable compounds where the payload and the ligand can compete for the same shell space. We evaluate drug–lipid compatibility, loading method, leakage, particle stability, and ligand accessibility together, using lipid nanoparticles for small molecule delivery as the base. | Inquiry |
| Small Molecule-LNP Development for Hydrophobic and Amphiphilic Compounds | For compounds that prefer the lipid phase, loading is screened through hydrophobic payload encapsulation in LNPs, with attention to whether the payload displaces the ligand–lipid from the shell. | Inquiry |
| Small Molecule-LNP Development for Fluorescent and Imaging Payloads | Supports labeled RNA, dyes, and tracking probes used to follow uptake, intracellular localization, and distribution trends. See fluorescent-labeled lipid nanoparticles for labeling options that do not disturb ligand display. | Inquiry |
| Small Molecule-LNP Development for Co-Delivery Systems | Developed for two-payload designs such as RNA plus small molecule, or antigen plus adjuvant, where ratio control and particle uniformity drive the result. Base methods come from lipid nanoparticles for co-delivery. | Inquiry |
Small molecule-conjugated LNP programs usually fail for a small number of recurring reasons. BOC Sciences works through them with measured data rather than by changing one variable at random.
✔ Strong Uptake but Weak Functional Payload Delivery
High association with the cell membrane does not mean the payload reached the cytosol. We separate binding, internalization, and release by pairing uptake data with localization imaging and LNP endosomal escape evaluation, then adjust ionizable lipid or helper lipid content where the block actually is.
✔ Weak Binding Strength of Monovalent Ligands
Many small ligands bind their receptor weakly once displayed at a single copy. We raise apparent affinity through multivalent presentation, ligand clustering, spacer length tuning, and density adjustment, then confirm the gain with a competition assay rather than with uptake alone.
✔ Ligand Buried by PEG Layer or Protein Corona
A small ligand is easier to hide than an antibody. We vary background PEG length and content using pegylated lipid nanoparticle design rules, create a spacer overhang, and repeat the uptake assay in serum to see whether the ligand is reachable under realistic conditions.
✔ Poor Ligand Solubility Disrupting Assembly
Hydrophobic or highly charged ligands precipitate during mixing and produce broad, unstable particles. We screen co-solvent fraction, mixing temperature, and lipid concentration through LNP solvent screening services before locking the preparation method.
✔ Particle Destabilization After Ligand-Lipid Incorporation
Adding a charged or bulky conjugate can raise size, widen PDI, or flip surface charge. We rebalance lipid ratios and surface charge with LNP zeta potential optimization, then check payload retention and short-term stability on the corrected formulation.
✔ Higher Uptake Without Improved Cell Selectivity
Uptake often rises in every cell line, which means the ligand is not doing the work. We build receptor-positive and receptor-low model pairs, add free-ligand competition and receptor-blocking arms, and report selectivity as a ratio so the ligand contribution can be judged directly.
BOC Sciences helps research teams troubleshoot ligand exposure, weak binding strength, ligand solubility, particle instability, and functional delivery readouts.
We start with the receptor, the cell or tissue model, the payload class, and the readout that will decide success. We also ask what the current unmodified LNP already does, because the ligand only has to beat that baseline in a measurable way. This step sets the acceptance criteria for the whole program.
We select the ligand chemotype, choose the attachment point that preserves the pharmacophore, and build the conjugate with the lipid anchor and PEG spacer that suit the intended route. Each conjugate is purified and confirmed before formulation, and we usually prepare more than one variant so the comparison is meaningful later.
Candidates are prepared across a ligand density grid with matched unmodified controls. During LNP process optimization we adjust lipid ratio, payload loading, solvent composition, mixing conditions, and buffer exchange until particle size, PDI, encapsulation, and measured ligand content are all in range.
Each candidate is reported on particle attributes, ligand content, ligand accessibility, uptake selectivity, and payload function. Where the project needs it, we extend to nanoparticle cellular and in vivo evaluation for distribution and activity trends, and we deliver the control data alongside the ligand data so the conclusion is defensible.
Small molecule-conjugated LNPs are used wherever the native liver bias of a standard LNP does not match the biology of the program. BOC Sciences supports ligand-bearing formulation work across the application areas below.
Whether your application is listed above or involves a different targeting goal, BOC Sciences can help turn your idea into a feasible development plan through small-molecule ligand design, conjugate synthesis, LNP formulation, and functional evaluation.
Challenge: A folate-siRNA LNP showed improved tumor-cell uptake in serum-free conditions, but its targeting advantage disappeared in 10% serum, and knockdown varied between experiments. The team needed to verify receptor-mediated delivery.
Diagnosis: Folate content met the target, but ligand-bearing PEG matched the background PEG length, leaving folate partially buried. Non-specific adsorption exaggerated uptake without serum, while protein corona formation exposed weak receptor-specific binding.
Solution: We rebuilt the conjugate design and the assay design in parallel. On the chemistry side, we synthesized folate-PEG2000-DSPE and folate-PEG3400-DSPE and paired each with a shorter PEG1000-DMG background to create a spacer overhang. On the formulation side, we ran a 0.25 / 0.5 / 1 / 2 mol% density grid against a matched unmodified LNP, then repeated the uptake panel in 10% serum with a 1 mM free-folic-acid competition arm and a receptor-low cell line as the negative comparison. Candidates were ranked on size, PDI, encapsulation efficiency, measured surface folate, uptake ratio, and knockdown.
Result: The 0.5 mol% folate-PEG2000 candidate averaged 95 nm (PDI below 0.18) with over 90% encapsulation. Serum uptake increased 3-fold, while knockdown reached 70% versus 25% for controls. Free-folate competition reduced knockdown to 30%, supporting receptor-mediated delivery.
Challenge: An mRNA-LNP accumulated mainly in the liver rather than bone in animal models. The team needed bisphosphonate attachment without disrupting particle formulation.
Diagnosis: Bisphosphonate acidity and metal-binding properties disrupted ethanol-phase assembly, producing larger, polydisperse particles. The ligand also required outward surface exposure for hydroxyapatite binding.
Solution: We chose post-insertion rather than co-assembly so the core mRNA formulation stayed untouched. A bisphosphonate-PEG2000-lipid conjugate was synthesized, confirmed by LC-MS, and prepared as micelles, then inserted into preformed mRNA-LNPs under controlled temperature and pH. We screened 0.5, 1, 2, and 3 mol% input levels and measured the actual inserted fraction instead of relying on feed ratio. Bone affinity was ranked first with a hydroxyapatite bead binding assay, and particle quality, mRNA integrity, encapsulation efficiency, and cell-level expression were checked on the same batches before any distribution work.
Result: The 2 mol% candidate showed the strongest hydroxyapatite binding, with particles near 110 nm, PDI below 0.20, and over 85% encapsulation. Cell-level mRNA expression and bone-associated distribution improved versus controls. The client obtained an optimized insertion protocol and binding assay.
Ligand Synthesis and LNP Formulation Capabilities
Ligand chemistry and particle formulation sit in one workflow, so a synthesis result feeds directly into formulation decisions. This builds on our lipid nanoparticle formulation experience across RNA, protein, and small-molecule payloads.
Flexible Small-Molecule Surface Modification Strategies
Co-assembly, post-insertion, covalent coupling, and affinity attachment are all available, and the route is chosen by screening rather than by convenience. Ligand variant comparison is supported by LNP lipid library screening services.
Quantitative Ligand Characterization and Targeting Evaluation
We report ligand content and ligand accessibility as separate numbers, and we design receptor-positive, receptor-low, and competition arms into the assay from the start.
Payload-Specific Process Optimization and Project Support
Loading conditions, solvent composition, and mixing parameters are set per payload class, then checked across repeated preparations so results hold from screening batch to larger batch.
Ligand Chemistry and Conjugation Capability
We handle conjugation site selection, spacer design, multivalent presentation, and conjugate purification, and we flag chemistries with known stability liabilities before a client commits to them.
Small-molecule ligands can improve lipid nanoparticle targeting by introducing specific molecular interactions with receptors or binding sites on target cells and tissues. For example, folate ligands can interact with folate receptors, while GalNAc derivatives are widely studied for hepatocyte targeting through the asialoglycoprotein receptor. Bisphosphonate ligands provide a different mechanism by promoting binding to bone mineral surfaces. However, increased cellular uptake does not necessarily translate into improved payload delivery. Effective targeting depends on ligand accessibility, receptor expression, particle composition, intracellular trafficking, and payload release. These parameters should be evaluated together using appropriate controls to distinguish ligand-dependent targeting from nonspecific nanoparticle uptake.
Common strategies include pre-synthesized ligand-lipid conjugate co-assembly, post-insertion, and covalent coupling to preformed LNP surfaces. Co-assembly incorporates ligand-functionalized lipids during particle formation and is suitable when the conjugate is compatible with the formulation process. Post-insertion allows ligand-bearing lipids to be introduced into existing LNPs, potentially reducing interference with initial payload encapsulation. Covalent coupling provides another option when suitable reactive groups are available on the ligand and particle surface. Non-covalent attachment may also be explored for selected ligand systems. The optimal method depends on ligand chemistry, solubility, surface density requirements, payload stability, and the intended targeting mechanism.
Ligand density influences receptor accessibility, nanoparticle interactions, cellular uptake, and formulation stability. Insufficient surface ligand density may produce weak target binding, while excessive ligand incorporation can alter particle assembly, increase aggregation, or reduce effective receptor engagement through steric crowding. PEG spacer length and background PEG coverage also determine whether small-molecule ligands remain accessible at the nanoparticle surface. Therefore, increasing ligand density does not always improve delivery performance. A systematic optimization strategy should compare multiple ligand concentrations while monitoring particle size, polydispersity, encapsulation, target-cell uptake, and functional payload activity. The preferred formulation is the one that balances selective targeting with reliable intracellular delivery.
Yes. BOC Sciences supports customized small molecule-conjugated LNP development for established targeting ligands, modified ligand derivatives, and novel small-molecule structures. Our services begin with evaluating the ligand's chemical structure, functional groups, solubility, and compatibility with lipid conjugation. Depending on project requirements, we can support ligand modification, linker design, ligand-lipid conjugate synthesis, and selection of suitable surface incorporation strategies. We then develop and optimize LNP formulations based on payload characteristics and targeting objectives. Particle characterization and functional evaluation can be incorporated to compare candidate formulations. This integrated approach helps researchers investigate new targeting concepts and identify technically feasible small molecule-LNP development strategies.
BOC Sciences provides physicochemical characterization and functional evaluation services to support small molecule-conjugated LNP development. Depending on project requirements, testing can include particle size distribution, polydispersity index, zeta potential, payload encapsulation, ligand incorporation, and surface ligand accessibility. We also support stability studies under relevant handling or biological conditions. For targeting evaluation, researchers can compare modified LNPs with unmodified controls using cellular uptake assays, receptor competition experiments, intracellular localization analysis, and payload-specific functional readouts. When appropriate, additional studies can investigate tissue distribution and ligand-dependent delivery behavior. These evaluations help identify formulation limitations, understand targeting mechanisms, and guide further optimization of small molecule-functionalized LNP systems.
